News Releases

Investor Alerts

Feb 11, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in February
Jan 8, 2020

Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.

Phase 1 Clinical Studies to begin in First Half of 2020
Dec 4, 2019

Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn's and Colitis Foundation's IBD Innovate Conference

IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system
Nov 25, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in December
Nov 19, 2019

Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips
Nov 7, 2019

Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity
Nov 5, 2019

Immunic, Inc. to Participate in Industry and Investor Conferences in November
Oct 15, 2019

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson
Oct 10, 2019

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

- Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 -
Sep 30, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in October

Show per page

f